指南与共识胸部肿瘤放疗姑息放疗与转移瘤

COVID-19大流行期间肺癌放疗实践建议:ESTRO-ASTRO共识声明

Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement.
指南 / 共识 · Radiother Oncol · 2020-04-06

由ESTRO与ASTRO认可的32位肺癌放疗专家通过改良Delphi共识流程,针对两种大流行情景(早期风险缓解与后期资源减少)下的六类常见肺癌病例制定放疗适应建议。核心推荐在风险缓解情景下不应偏离指南推荐放疗以免损害预后,COVID-19阳性患者一般建议推迟或中断放疗;在资源减少需分诊时,分诊因素包括治愈可能性、放疗相对获益、预期寿命和体能状态。

要点

  • 风险缓解情景下不应偏离指南推荐放疗以免损害肺癌患者预后
  • COVID-19阳性患者一般建议推迟或中断放疗以避免暴露风险
  • 资源严重减少需分诊时考虑治愈可能性、放疗相对获益、预期寿命和体能状态

核心结论

  • 该ESTRO-ASTRO联合实践建议针对COVID-19大流行下肺癌放疗常见临床情景建立了务实且平衡的共识推荐。

研究设计与样本

  • 由32位肺癌放疗专家参与的改良Delphi共识流程,为ESTRO与ASTRO认可项目。
  • 评估两种大流行情景:早期风险缓解情景与后期资源减少需分诊情景。
  • 评估六类常见肺癌病例:周围型I期NSCLC、局部晚期NSCLC、pN2 NSCLC切除术后放疗、局限期SCLC的胸部放疗与预防性颅脑照射、IV期NSCLC姑息胸部放疗。

主要发现

  • 风险缓解情景下应努力不偏离指南推荐放疗实践以免损害肺癌患者预后。
  • 同一情景下COVID-19阳性患者一般建议推迟或中断放疗以避免癌症患者与工作人员暴露风险增加。
  • 资源减少的严重大流行情景下如需分诊,重要因素包括治愈可能性、放疗相对获益、预期寿命和体能状态。
  • 提供了关于多模态治疗策略和放疗分次的病例特异性共识推荐。

关键数值与推荐

  • 风险缓解情景:不偏离指南推荐放疗实践以不损害预后。
  • 风险缓解情景:COVID-19阳性患者一般建议推迟或中断放疗。
  • 资源减少情景分诊因素:治愈可能性、放疗相对获益、预期寿命、体能状态。

临床怎么用

  • 早期风险缓解阶段应维持指南推荐的肺癌放疗实践,避免因疫情随意改变方案而损害预后。
  • 对COVID-19阳性肺癌患者一般应推迟或中断放疗,以降低患者与工作人员感染暴露风险。
  • 资源严重减少需分诊时,综合治愈可能性、放疗相对获益、预期寿命和体能状态进行病例特异性决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The COVID-19 pandemic has caused radiotherapy resource pressures and led to increased risks for lung cancer patients and healthcare staff. An international group of experts in lung cancer radiotherapy established this practice recommendation pertaining to whether and how to adapt radiotherapy for lung cancer in the COVID-19 pandemic. METHODS: For this ESTRO & ASTRO endorsed project, 32 experts in lung cancer radiotherapy contributed to a modified Delphi consensus process. We assessed potential adaptations of radiotherapy in two pandemic scenarios. The first, an early pandemic scenario of risk mitigation, is characterized by an altered risk-benefit ratio of radiotherapy for lung cancer patients due to their increased susceptibility for severe COVID-19 infection, and minimization of patient travelling and exposure of radiotherapy staff. The second, a later pandemic scenario, is characterized by reduced radiotherapy resources requiring patient triage. Six common lung cancer cases were assessed for both scenarios: peripherally located stage I NSCLC, locally advanced NSCLC, postoperative radiotherapy after resection of pN2 NSCLC, thoracic radiotherapy and prophylactic cranial irradiation for limited stage SCLC and palliative thoracic radiotherapy for stage IV NSCLC. RESULTS: In a risk-mitigation pandemic scenario, efforts should be made not to compromise the prognosis of lung cancer patients by departing from guideline-recommended radiotherapy practice. In that same scenario, postponement or interruption of radiotherapy treatment of COVID-19 positive patients is generally recommended to avoid exposure of cancer patients and staff to an increased risk of COVID-19 infection. In a severe pandemic scenario characterized by reduced resources, if patients must be triaged, important factors for triage include potential for cure, relative benefit of radiation, life expectancy, and performance status. Case-specific consensus recommendations regarding multimodality treatment strategies and fractionation of radiotherapy are provided. CONCLUSION: This joint ESTRO-ASTRO practice recommendation established pragmatic and balanced consensus recommendations in common clinical scenarios of radiotherapy for lung cancer in order to address the challenges of the COVID-19 pandemic.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Guckenberger M, Belka C, Bezjak A, et al. Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. Radiother Oncol. 2020. PMID: 32342863. doi:10.1016/j.radonc.2020.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。